$ASEP Through two products in development, $ASEP is looking to solve the problems of misuse and late diagnosis, as well as antibiotic-resistant infections.
$ASEP has proven its technology to be able to accurately diagnose life-threatening sepsis infections in a fraction of the time that traditional methods can, leading to faster and more effective treatment. Additionally, $ASEP is currently in the development of a therapeutic peptide technology that is able to treat currently untreatable antibiotic-resistant biofilm infections.
With the current outlook on the antibiotic market being as it is, I think $ASEP is positioning itself to be a company in high demand in the near future. By addressing the demand for both diagnosis and treatment there is a sizable share of the market that the company can capitalize on.
$ASEP is trading at $.6 and evaluated at a market cap of $33.68 million. There is some huge growth potential should $ASEP effectively capture even a small portion of the multi-billion dollar market.
https://asepmedical.com/